BioSpace News Archive

Cytovia Therapeutics, Inc., and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), announced today that they have expanded their collaboration of TALEN® gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.

Personalis, Inc. (Nasdaq: PSNL), announced today that its management will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021.

Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of the Company’s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in adult patients with hypoparathyroidism (HP).

RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect in infants.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata,” “us,” “our,” or the “Company”), today provided an update on its development programs reflecting sustained clinical progress and a strengthened financial position.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that it is giving notice of its intention to redeem the following Senior Notes, representing an aggregate total principal amount of approximately $2.2 billion, on December 3, 2021.

Elevation Oncology, Inc. today announced that members of the senior management team will present a corporate overview and participate in one-on-one investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place November 29, 2021 to December 2, 2021.

Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference.

Better Therapeutics, Inc today announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of type 2 diabetes.